Coherence Neuro Raises $10 Million Seed to Advance Closed‑Loop Neurotechnology for Cancer Treatment
Coherence Neuro, a San Francisco‑based neurotechnology startup pioneering a new approach to managing cancer, has successfully closed a $10 million seed funding round to accelerate development of its therapeutic platform and begin first‑in‑human trials. The financing underscores growing venture capital interest in platforms that combine brain‑computer interface technology with real‑time disease management.
Founded in 2022 by Ben Woodington and Elise Jenkins, Coherence Neuro works at the intersection of neuroengineering, oncology and machine learning to design implantable and wearable systems that monitor neural activity and deliver targeted stimulation tailored to each patient’s physiology. The company’s flagship device, SOMA‑1, is designed as a closed‑loop bioelectronic system that listens to electrical signals associated with disease progression and then applies adaptive stimulation to disrupt harmful signaling pathways and restore biological balance. The platform also contributes continuous, high‑resolution data to an integrated learning network that refines treatment algorithms over time.
The $10 million seed round, announced in November 2025, was led by Topology Ventures and Artesian (Alternative Investments), two venture firms with a track record of backing deep‑tech and health‑tech innovations. Participation in the round came from an array of other investors, each bringing strategic insight and early‑stage capital to support Coherence Neuro’s mission. These included continued support from existing backers like Blackbird and Possible Ventures, as well as contributions from XEIA Venture Partners, Jumpspace Ventures, Divergent Capital, SmartGateVC, Spacewalk VC and other angel investors such as Matt Krisiloff, Linhao Zhang, and Tim Shi.
Coherence Neuro’s multidisciplinary approach reimagines cancer not as an external invader but as a system‑state error that can be managed and corrected by reading and modulating the body’s electrical patterns. Founders describe their technology as a departure from conventional one‑directional treatments like surgery, radiation, and chemotherapy, aiming instead for continuous, adaptive care delivered via precision stimulation informed by real‑time data.
With the fresh capital, Coherence Neuro plans to advance its first human clinical trials, a critical step toward validating the SOMA‑1 platform in patients and bringing its vision closer to reality. Early‑stage testing will focus on conditions such as glioblastoma, one of the most aggressive forms of brain cancer. The company believes that closed‑loop electrical monitoring and intervention could improve outcomes by continuously adjusting therapy based on how the disease evolves, rather than relying on intermittent clinical assessments.
Leadership emphasizes that this funding round not only unlocks near‑term experimental milestones but also sets the stage for building a broader data ecosystem. As each implanted device contributes physiological signals and patient outcomes, the collective dataset can feed advanced AI and machine‑learning models, enabling more precise predictions and personalised therapies over time. By aggregating longitudinal neural data across participants, Coherence Neuro aims to refine its technology into a responsive, learning treatment network that benefits all users.
Investors have expressed confidence in Coherence Neuro’s potential to transform cancer care through its foundational platform. One partner highlighted the company’s ability to translate decades of neuroscience research into a new category of cancer management tools, anticipating that closed‑loop bioelectronic systems may one day complement or replace aspects of traditional therapy by restoring biological equilibrium with minimal side effects.
Coherence Neuro’s $10 million seed financing brings the company closer to achieving key milestones in clinical validation and regulatory progress. As it moves into 2026, the startup will focus on refining its implantable technology, expanding its team of engineers and clinical experts, and establishing partnerships with research institutions and healthcare providers to support upcoming trials. The startup’s journey reflects broader growth in health technology investment, where ambitious startups are leveraging AI, bioelectronics and neural interfaces to tackle complex diseases with innovative, data‑driven solutions.
With its strengthened financial backing and a clear path toward first‑in‑human studies, Coherence Neuro is poised to play a significant role in the future of therapeutic neurotechnology — potentially redefining how cancer is monitored, treated and understood in the decades to come.
